Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Carboplatin
/ administration & dosage
Doxorubicin
/ administration & dosage
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Neoplasm Staging
Neutropenia
/ chemically induced
Ovarian Neoplasms
/ blood
Paclitaxel
/ administration & dosage
Polyethylene Glycols
/ administration & dosage
Prognosis
Progression-Free Survival
Prospective Studies
Retrospective Studies
Chemotherapy-induced neutropenia
Cytotoxic dosing methods
Meta-analysis
Ovarian cancer
Prognostic factors
Retrospective-prospective design
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
11
02
2019
revised:
03
04
2019
accepted:
07
04
2019
pubmed:
29
4
2019
medline:
27
8
2019
entrez:
29
4
2019
Statut:
ppublish
Résumé
Chemotherapy-induced neutropenia (CIN) has been associated with improved prognosis in several cancer conditions. Contrasting data have been produced in ovarian cancer.
Sections du résumé
BACKGROUND
Chemotherapy-induced neutropenia (CIN) has been associated with improved prognosis in several cancer conditions. Contrasting data have been produced in ovarian cancer.
Identifiants
pubmed: 31029508
pii: S0090-8258(19)30507-4
doi: 10.1016/j.ygyno.2019.04.012
pii:
doi:
Substances chimiques
liposomal doxorubicin
0
Polyethylene Glycols
3WJQ0SDW1A
Doxorubicin
80168379AG
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Langues
eng
Pagination
83-88Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.